Table 3.
Associations between MPNs and cytokines.
| Inflammatory marker∗ | Impact | Disorder |
|---|---|---|
| B2MICG | Symptoms | MF |
| BMP1 | Disease advancement | PMF |
| BMP6 | Disease advancement | PMF |
| BMP7 | Disease advancement | PMF |
| BMP-Rcp2 | Disease advancement | PMF |
| CD40L | Loss of appetite | MF |
| CRP | Thrombosis; atherogenesis | PV, ET |
| Ferritin | Pruritus | MF |
| FGF | Marrow fibrosis | PV, ET, PMF |
| HGF | Splenomegaly | PMF |
| IFN | Associated with JAK2V617F | MF |
| IL-12 | Inferior survival; transfusion requirements, vascular complications | MF |
| IL-15 | Inferior survival | MF |
| IL-17A | Associated with JAK2V617F | MF |
| IL-1B | Associated with JAK2V617F | MF |
| IL-1RA | Splenomegaly | PMF |
| IL-2R | Inferior survival; transfusion requirements | MF |
| IL-8 | Elevated blasts; constitutional symptoms | MF |
| IL-8 | Associated with JAK2V617F | MF |
| IP-10 | Inferior survival | MF |
| LEPTIN | Symptoms; weight loss | MF |
| MIG | Splenomegaly | PMF |
| PAL1 | Insomnia | MF |
| PTX | Thrombosis; atherogenesis | PV, ET |
| RANTES | Insomnia | MF |
| TIMP1 | Symptoms | MF |
| TNF-1 | Clonal expansion | JAK2V617F+ MPNs |
| TNFRII | Symptoms | MF |
| VCAM1 | Symptoms | MF |
| VEGFb | Marrow fibrosis | PV, ET, PMF |
ET: essential thrombocythemia; MF: myelofibrosis; MPN: myeloproliferative neoplasm; PMF: primary myelofibrosis; PV: primary myelofibrosis.
∗Refer to Table 2 for definition.